Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
In an ACR Convergence session, two rheumatologists discussed how COVID-19 changed the use of telemedicine, how payers reacted and which changes are likely permanent and which are likely to be temporary.
Through the development of a multidisciplinary musculoskeletal institute, we have created a model that facilitates coordination of care of complex patients between medical and surgical subspecialists, physical therapists, dieticians and social workers. A case is presented to demonstrate the improved care experience for both patients and providers and to share our learnings more broadly. The…
During ACR Convergence 2020 in early November, the ACR and ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards and the ACR’s Distinguished Fellows. In addition, we bring you the first ever…
Implementation of rate increases for evaluation and management services and other changes bring big updates to many Current Procedural Terminology codes.
Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.
While an active member of her state rheumatology society, L. Manuela Marinescu, MD, saw the value of connecting with other regional groups to share information and advocacy strategies. On Nov. 16, she assumed the role of chair of the ACR’s Affiliate Society Council (ASC), where she will help facilitate those connections. Dr. Marinescu graduated with…
From pain management to arthroplasty, African American patients with OA and RA experience worse outcomes than white patients. But the reasons for these health disparities are difficult to parse from socioeconomic and cultural factors.
Polly J. Ferguson, MD, Jessica Lynton, PharmD, BCPS, & Beth H. Resman-Targoff, PharmD, FCCP, on behalf of the ARP Membership & Nominations Committee |
The number of medications with rheumatologic indications has increased in parallel with expanding complexities of medication approval and delivery. Simply starting a patient on a biologic medication or new disease-modifying anti-rheumatic drug (DMARD) can be time consuming and frustrating for physicians, nurses and their support staff. In addition to educating the patient and obtaining prior…